A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Regadenoson (Primary)
- Indications Reperfusion injury
- Focus Adverse reactions
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 10 Mar 2017 New trial record